Castle Biosciences Announces New York State Department of Health Approval of Its TissueCypher® Barrett’s Esophagus Test (Business Wire)

Castle Biosciences has achieved a significant milestone with New York State Department of Health approval for its TissueCypher® Barrett’s Esophagus test, the first AI-driven precision medicine tool designed to predict progression from Barrett’s Esophagus (BE) to esophageal cancer. This breakthrough enables personalized surveillance strategies or early interventions, addressing the rising incidence of esophageal cancer, one of the deadliest cancers in the U.S. By integrating advanced biomarkers and spatial biology, TissueCypher provides critical risk assessments for patients. Could this innovation redefine cancer prevention and treatment?